Description:SGC-CBP30, with the CAS number 1613695-14-9, is a small molecule inhibitor that specifically targets the bromodomain and extraterminal (BET) family of proteins, particularly BRD4. This compound is known for its role in modulating gene expression by disrupting the interaction between BET proteins and acetylated lysines on histones, which is crucial for the transcriptional regulation of various genes involved in cancer and inflammation. SGC-CBP30 has been studied for its potential therapeutic applications in various cancers, as it may help in reducing the proliferation of cancer cells by altering the expression of oncogenes. Additionally, it has shown promise in preclinical studies for its ability to penetrate cells effectively and exhibit selective inhibition. The compound is typically characterized by its molecular structure, which includes specific functional groups that contribute to its biological activity. As research continues, SGC-CBP30 may provide insights into the development of novel treatments targeting BET proteins in various diseases.
2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propyl]-1H-1,3-benzodiazole (DCPI) is a cancer drug that inhibits the activity of DNA topoisomerase II. It …
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![2-[2-(3-Chloro-4-methoxyphenyl)ethyl]-5-(dimethyl-1,2-oxazol-4-yl)-1-[(2S)-2-(morpholin-4-yl)propy…](https://static.cymitquimica.com/products/3D/thumb/NPC69514.jpg)
